Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for nanotechnology industry professionals · Friday, March 29, 2024 · 699,712,479 Articles · 3+ Million Readers

Cyramza (ramucirumab; Eli Lilly/Shire) Drug Profile 2017-2026

Dublin, June 20, 2019 (GLOBE NEWSWIRE) -- The "Cyramza" drug pipelines has been added to ResearchAndMarkets.com's offering.

Cyramza (ramucirumab; Eli Lilly/Shire) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 found on tumor vasculature.

The VEGF protein is an essential component of the angiogenesis pathway, which is critical for blood vessel formation, tumor growth, invasion, and metastasis.

Cyramza inhibits tumor angiogenesis by preventing VEGF ligands VEGF-A, VEGF-C, and VEGF-D from binding to and activating the VEGFR-2 receptor, which in turn prevents the proliferation and migration of endothelial cells necessary for angiogenesis to occur. The lack of new blood vessels starves the tumors of their nutrient supply, resulting in tumor growth inhibition.

Key Topics Covered:

  1. Drug Overview
  2. Product Profiles
  3. Cyramza: Non-small cell lung cancer (NSCLC)
  4. Cyramza: Gastric cancer
  5. Cyramza: Colorectal cancer (CRC)
  6. Cyramza: Hepatocellular carcinoma (HCC)

LIST OF FIGURES
The authors drug assessment summary for Vargatef in non-small cell lung cancer
The authors drug assessment summary for Xalkori in non-small cell lung cancer
Xalkori sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
Zykadia for non-small cell lung cancer - SWOT analysis
Cyramza for colorectal cancer - SWOT analysis
The authors drug assessment summary of Cyramza for colorectal cancer
The authors drug assessment summary for Zykadia in non-small cell lung cancer
Zykadia sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
Capmatinib for non-small cell lung cancer - SWOT analysis
The authors drug assessment summary of Cyramza for hepatocellular carcinoma
The authors drug assessment summary for capmatinib in non-small cell lung cancer
Capmatinib sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
Cemiplimab for non-small cell lung cancer - SWOT analysis

LIST OF TABLES
Cyramza drug profile
Cyramza pivotal trial data in non-small cell lung cancer
Cyramza ongoing late-phase clinical trials in non-small cell lung cancer
Vargatef patient numbers for NSCLC across the five major EU markets, by country, 2017-26
Cyramza sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017-26
Cyramza drug profile
Cyramza pivotal trial data in gastric cancer
Cyramza sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Cyramza patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Cyramza drug profile
Cyramza Phase III data in colorectal cancer
Cyramza Phase I trials in colorectal cancer
Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
Patients treated with Cyramza across the US, Japan, and five major EU markets, by country, 2016-25
Cyramza drug profile
Zykadia patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
Cyramza Phase III trial in HCC
Cyramza Phase II data in HCC
Cyramza drug profile
Cyramza pivotal trial data in gastric cancer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/3h600l

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Lung Cancer Drugs , Colon Cancer Drugs 
                    

22157.jpg

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release